黄熱ワクチン市場：治療タイプ別、エンドユーザー別、地域別、2026～2032年

黄熱ワクチン市場の評価-2026～2032年

流行国への入国にワクチン接種の遵守が求められる海外渡航の増加や、アクセシビリティと有効性を向上させるワクチンの技術開発が黄熱ワクチン市場を牽引しています。Verified Market Researchのアナリストによると、黄熱ワクチン市場は、2023年には約1億4,487万米ドルを下回り、予測期間中に2億1,864万米ドルの評価額に達すると推定されています。

世界の健康への取り組みと黄熱病の脅威に関する知識の増加は、特に流行地域が拡大し、より多くの旅行者が個人的な安全のために予防接種を求めるにつれて、需要を押し上げています。これにより、市場は2026～2032年にかけてCAGR 5.28%で成長します。

黄熱ワクチン市場定義/概要

黄熱ワクチンは、主にアフリカや南米で蚊によって媒介される危険な病気である黄熱を予防するために使用される弱毒生ウイルスワクチンです。1回の皮下投与で生涯予防が可能なことが多く、流行地域に住んでいる人や流行地域に行く人には欠かせないです。また、このワクチンは特定の国への入国にも必要であり、国際的な旅行衛生規則における重要性を示しています。黄熱ワクチンは、個人の予防にとどまらず、アウトブレイク対策にも重要であり、リスクのある集団への定期予防接種が推奨されるなど、世界の公衆衛生の取り組みに大きく貢献しています。

黄熱ワクチンの普及を促進する主要因とは？

世界の旅行、特に黄熱流行国への旅行の増加が黄熱ワクチンの需要を高めています。世界観光機関（UNWTO）によると、2019年の国際観光客の入国者数は15億人で、このうち黄熱病が流行している地域への旅行者がかなりの割合を占めています。米国疾病予防管理センター（CDC）によると、2019年に黄熱病の予防接種が推奨または必要な国を訪れた米国人は900万人近くに上りました。

気候変動と都市化が黄熱リスク地域の拡大に寄与しており、ワクチン接種の需要が高まっています。世界保健機関（WHO）によると、2017～2018年にかけて、南北アメリカの7カ国で、以前はリスクがないと考えられていた地域を含む、確認された黄熱病患者が報告されました。2017年7月から2018年6月にかけて、ブラジルでは1,376件の黄熱の確認例が報告され、脅威の増大と予防接種の必要性が浮き彫りになりました。

さらに、各国政府や国際保健機関は、黄熱の流行を防ぐために大規模なワクチン接種プログラムを実施しています。WHOとユニセフによると、2016～2017年にかけてアンゴラとコンゴ民主共和国で黄熱病が流行した際、緊急キャンペーンで約3,000万人が予防接種を受けた。また、WHOの黄熱病撲滅（EYE）イニシアチブは、2026年までに10億人にワクチンを接種することを目指しており、黄熱ワクチンの需要を高めています。

黄熱ワクチン市場の成長を妨げる課題は？

黄熱ワクチンの潜在的な副作用が市場成長の大きな障壁となっています。一般的な副作用には、頭痛、筋肉痛、疲労感などがあり、これがワクチン接種を敬遠させる要因となっています。こうした副作用に対する懸念は、特に予防接種に対してすでに警戒心を抱いている人々の間で、需要減少の一因となっています。このようなためらいは、黄熱病の発生を抑えることを目的とした予防接種の全体的な効果を低下させています。

さらに、インフラのボトルネックも市場に大きな影響を与えています。輸送や保管中に有効性を維持するためには、先進的コールドチェーン物流によって予防接種を配布しなければならないです。多くの流行地域では、限られたヘルスケア施設と物流の障害が、タイムリーな予防接種の取り組みを妨げています。こうした制約が脆弱な人々のワクチンへのアクセスを制限し、結果的に黄熱病の蔓延を防ぐ試みを妨げ、市場の成長に影響を与えています。

目次

第1章 黄熱ワクチンの世界市場導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 黄熱ワクチンの世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 黄熱ワクチンの世界市場：治療タイプ別

• 概要
• 疼痛管理薬
• 経口補水

第6章 黄熱ワクチンの世界市場：エンドユーザー別

• 概要
• 病院
• 診断センター
• ポイントオブケアセンター
• その他

第7章 黄熱ワクチンの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他
  • ラテンアメリカ
  • 中東・アフリカ

第8章 黄熱ワクチンの世界市場競合情勢

• 概要
• 各社の市場ランキング
• 主要開発戦略

第9章 企業プロファイル

• Takeda Pharmaceutical Company Ltd
• Merck & Co Inc
• GlaxoSmithKline PLC
• Biological E Limited
• Panacea BIoTec
• iBio Inc
• FSUE Chumakov
• Institut Pasteur de Dakar
• Bio Manguinhos
• Sanofi Pasteur SA

第10章 主要開発

• 製品上市/開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第11章 付録

• 関連調査

Yellow Fever Vaccine Market Valuation - 2026-2032

The rising international travel, which requires vaccination compliance for admission into endemic countries, and technological developments in vaccines that improve accessibility and efficacy are driving the Yellow Fever Vaccine Market. According to the analyst from Verified Market Research, the Yellow Fever Vaccine Market is estimated to reach a valuation of USD 218.64 Million over the forecast subjugating around USD 144.87 Million in 2023.

The global health initiatives and increased knowledge of yellow fever threats are driving up demand, especially as endemic zones grow and more travelers seek inoculation for personal safety. It enables the market to grow at a CAGR of 5.28% from 2026 to 2032.

Yellow Fever Vaccine Market: Definition/ Overview

The yellow fever vaccine is a live, attenuated virus vaccine used to prevent yellow fever, a dangerous disease spread mostly by mosquitos in Africa and South America. When given as a single subcutaneous dose, it often gives lifelong protection, making it critical for anyone living in or going to endemic areas. The vaccine is also necessary for entry into certain countries, demonstrating its importance in international travel health rules. The yellow fever vaccine has applications beyond individual protection; it is critical in outbreak control and is recommended for routine immunization in at-risk populations, considerably contributing to worldwide public health initiatives.

What are the Key Drivers that Foster the Adoption of Yellow Fever Vaccines?

The increase in worldwide travel, particularly to yellow fever-endemic countries, is driving up demand for yellow fever vaccines. According to the World Tourism Organization (UNWTO), international tourist arrivals totaled 1.5 billion in 2019, with a sizable proportion of these visitors traveling to areas where yellow fever is prevalent. According to the Centers for Disease Control and Prevention (CDC), nearly 9 million Americans visited countries where yellow fever vaccination is recommended or necessary in 2019.

Climate change and urbanization are contributing to the spread of yellow fever risk areas, increasing the demand for vaccination. According to the World Health Organization (WHO), seven nations in the Americas reported verified yellow fever cases between 2017 and 2018, including areas that were previously considered risk-free. Between July 2017 and June 2018, 1,376 confirmed cases of yellow fever were reported in Brazil, underscoring the growing threat and need for vaccinations.

Furthermore, governments and international health organizations are putting in place large-scale vaccination programs to prevent yellow fever epidemics. According to WHO and UNICEF, almost 30 million people were vaccinated in emergency campaigns during the yellow fever outbreaks in Angola and the Democratic Republic of the Congo in 2016-2017. Also, the WHO's Eliminate Yellow Fever Epidemics (EYE) initiative seeks to vaccinate 1 billion people by 2026, increasing demand for yellow fever vaccines.

What are the Challenges Hindering the Growth of the Yellow Fever Vaccine Market?

The potential negative effects of the yellow fever vaccine are a substantial barrier to market growth. Common adverse responses include headaches, muscle soreness, and exhaustion, which discourage people from getting vaccinated. Concerns about these side effects contribute to decreased demand, particularly among people who are already wary of immunizations. This hesitation reduces the overall effectiveness of vaccination initiatives aimed at limiting yellow fever outbreaks.

Furthermore, infrastructure bottlenecks have a big impact on the market. To preserve efficacy during shipping and storage, vaccinations must be distributed via sophisticated cold-chain logistics. In many endemic areas, limited healthcare facilities and logistical obstacles prevent timely immunization efforts. These constraints restrict vulnerable groups' access to vaccines, ultimately hampering attempts to prevent the spread of yellow fever and affecting market growth.

Category-Wise Acumens

What Factors Contribute to the Market Leadership of Oral Rehydration Treatment?

According to VMR analysis, the oral rehydration segment is estimated to hold the largest market share during the forecast period due to the high prevalence of dehydration associated with yellow fever, which demands rapid rehydration therapy as the first line of treatment. Oral rehydration treatments are effective in replacing lost fluids and electrolytes, making them necessary for patient recovery. This acute requirement for hydration promotes the demand for oral rehydration solutions in the market.

Health agencies such as the World Health Organization (WHO) and UNICEF strongly support oral rehydration as a critical treatment for yellow fever-induced dehydration, which is a further major concern. Their campaign not only promotes awareness but also inspires healthcare providers to prioritize oral rehydration products, resulting in increased market growth and acceptance by patients.

Furthermore, the growing availability and diversity of oral rehydration products help to maintain the segment's dominance. Formulation innovations like flavored liquids and effervescent tablets improve patient compliance and happiness. As these medications become more widely available through multiple distribution channels, they strengthen their position as the primary treatment for yellow fever-related dehydration.

What are the Key Driving Forces for the Yellow Fever Vaccines in Hospitals?

The hospital segment is estimated to dominate the Yellow Fever Vaccine Market during the forecast period due to the increasing dominance is increased vaccination awareness among visitors and local populations in endemic areas. Hospitals are key healthcare providers where people get immunizations, especially before going to locations where yellow fever is common. This increased knowledge results in an increase in hospital visits for immunizations, cementing their segment position.

The provision of comprehensive healthcare services in hospitals is a further significant factor driving the segment. These facilities not only provide vaccines but also offer pre-vaccination consultations and post-vaccination care, boosting patient trust and encouraging more people to get immunized. This integrated approach leads to higher immunization rates than in other contexts.

Furthermore, government initiatives and health programs focused on limiting yellow fever outbreaks prioritize hospital vaccination campaigns. Collaboration between hospitals and public health agencies ensures that vaccines are easily available, particularly during outbreaks or high travel seasons, bolstering hospitals' market position.

Country/Region-wise Acumens

What Drivers Contribute to the Sustained Dominance of North America in this Market?

According to VMR analyst, North America is estimated to dominate the Yellow Fever Vaccine Market during the forecast period. North America, particularly the United States, has a large number of international visitors to yellow fever endemic areas. According to the National Travel and Tourism Office of the United States Department of Commerce, 93.0 million Americans left the country for overseas travel in 2018 alone. According to the Centers for Disease Control and Prevention (CDC), nearly 9 million Americans visited countries where yellow fever vaccination is recommended or necessary in 2019. The increasing number of visitors to high-risk areas fuels the demand for yellow fever vaccines in the North American market.

Furthermore, North America, particularly the United States and Canada, has a well-developed healthcare and vaccination infrastructure. The CDC's Advisory Committee on Immunization Practices (ACIP) advises yellow fever immunization for visitors to endemic countries. In 2019, the CDC estimated that there were over 4,500 yellow fever vaccination clinics in the United States, ensuring extensive availability of the vaccine. This broad network of vaccination centers contributes to the region's dominant position in the Yellow Fever Vaccine Market.

What are the Factors Leading to Substantial Growth of the Market in Europe?

Europe region is estimated to exhibit substantial growth within the market during the forecast period. International travel in Europe has increased significantly, particularly to regions where yellow fever is widespread. According to the European Travel Commission, European outward travel grew by 7% in 2019, totaling 1.1 billion trips. The European Centre for Disease Prevention and Control (ECDC) reported 13 travel-associated yellow fever cases among European visitors between 2012 and 2018, emphasizing the importance of vaccination for European tourists visiting endemic locations. This expanding trend in foreign travel is a significant driver of the Yellow Fever Vaccine Market in Europe.

Furthermore, strong immunization and public health initiatives have been put in place by European nations to safeguard tourists. According to the World Health Organization's (WHO) European Region, there were over 7,000 authorized yellow fever vaccination facilities throughout Europe in 2019. According to France's National Public Health Agency, the number of yellow fever vaccination doses administered climbed from 169,000 in 2015 to 194,000 in 2019. The broad availability and use of yellow fever vaccinations help to drive market expansion in Europe.

Competitive Landscape

The competitive landscape of the Yellow Fever Vaccine Market is characterized by a dynamic interaction of innovation, regulatory compliance, and strategic alliances. As the demand for yellow fever immunization rises due to increased international travel and health advisories, stakeholders are working on improving vaccine efficacy and accessibility through advanced R&D projects.

Some of the prominent players operating in the Yellow Fever Vaccine Market include:

Takeda Pharmaceutical Company Ltd, Merck & Co, Inc., GlaxoSmithKline PLC, Biological E Limited, Panacea Biotec, iBio, Inc., FSUE Chumakov, Institut Pasteur de Dakar, Bio Manguinhos, and Sanofi Pasteur SA.

Latest Developments

In April 2021, Sanofi Pasteur announced that YF-VAX is now available for purchase in the United States. YF-VAX can now be ordered from the manufacturer by providers who have a current Yellow Fever Vaccination Stamp from their state or territory health department.

Yellow Fever Vaccine Market, By Category

• Treatment Type:
• Pain Management Drugs
• Oral Rehydration
• End-User:
• Hospitals
• Point-of-Care Centers
• Diagnostic Centers
• Others
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL YELLOW FEVER VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL YELLOW FEVER VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL YELLOW FEVER VACCINE MARKET, BY TREATMENT TYPE

• 5.1 Overview
• 5.2 Pain Management Drugs
• 5.3 Oral Rehydration

6 GLOBAL YELLOW FEVER VACCINE MARKET, BY END USER

• 6.1 Overview
• 6.2 Hospitals
• 6.3 Diagnostic Centers
• 6.4 Point of Care Centers
• 6.5 Others

7 GLOBAL YELLOW FEVER VACCINE MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East & Africa

8 GLOBAL YELLOW FEVER VACCINE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Takeda Pharmaceutical Company Ltd
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Merck & Co Inc
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 GlaxoSmithKline PLC
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Biological E Limited
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 Panacea Biotec
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 iBio Inc
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 FSUE Chumakov
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Institut Pasteur de Dakar
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Bio Manguinhos
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 Sanofi Pasteur SA
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research